Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares Purchased by Bank of America Corp DE
Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares Purchased by Bank of America Corp DE
Bank of America Corp DE increased its stake in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT – Get Rating) by 16.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,817,187 shares of the company's stock after acquiring an additional 260,871 shares during the quarter. Bank of America Corp DE owned about 2.79% of Global Blood Therapeutics worth $62,947,000 at the end of the most recent quarter.
根據美國銀行最近提交給美國證券交易委員會(美國證券交易委員會)的文件，第一季度美國銀行增持了全球血液治療公司(GIC：GET)的股份16.8%。該機構投資者在本季度增持了260,871股後，持有1,817,187股該公司股票。截至最近一個季度末，美國銀行DE擁有全球血液治療公司約2.79%的股份，價值62,947,000美元。
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SkyView Investment Advisors LLC raised its stake in Global Blood Therapeutics by 587.2% during the 1st quarter. SkyView Investment Advisors LLC now owns 804 shares of the company's stock worth $28,000 after acquiring an additional 687 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Global Blood Therapeutics by 75.6% in the first quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company's stock valued at $52,000 after purchasing an additional 650 shares during the period. Advisor Group Holdings Inc. increased its stake in Global Blood Therapeutics by 31.8% in the fourth quarter. Advisor Group Holdings Inc. now owns 1,865 shares of the company's stock valued at $55,000 after purchasing an additional 450 shares during the period. Cantor Fitzgerald L. P. acquired a new position in Global Blood Therapeutics in the first quarter valued at $208,000. Finally, FORA Capital LLC acquired a new position in Global Blood Therapeutics in the first quarter valued at $280,000.
其他對衝基金和其他機構投資者最近也買賣了該公司的股票。Skyview Investment Advisors LLC在第一季度將其在全球血液治療公司的持股增加了587.2%。Skyview Investment Advisors LLC現在持有804股該公司股票，價值2.8萬美元，該公司在上個季度增持了687股。NISA Investment Advisors LLC在第一季度增持了全球血液治療公司的股份75.6%。NISA Investment Advisors LLC現在擁有1,510股該公司的股票，價值52,000美元，在此期間又購買了650股。Advisor Group Holdings Inc.在第四季度增持了全球血液治療公司31.8%的股份。Advisor Group Holdings Inc.在此期間又購買了450股，現在擁有1,865股該公司股票，價值55,000美元。Cantor Fitzgerald L.P.在第一季度獲得了全球血液治療公司的一個新職位，價值20.8萬美元。最後，Fora Capital LLC在第一季度收購了全球血液治療公司的一個新頭寸，價值28萬美元。
Global Blood Therapeutics Stock Down 0.4 %
全球血液治療類股下跌0.4%
GBT stock opened at $67.75 on Tuesday. The company has a market cap of $4.57 billion, a P/E ratio of -13.52 and a beta of 0.46. Global Blood Therapeutics, Inc. has a 52 week low of $21.65 and a 52 week high of $73.02. The company's 50-day moving average price is $58.93 and its 200 day moving average price is $40.43. The company has a current ratio of 6.88, a quick ratio of 6.17 and a debt-to-equity ratio of 4.92.
GBT股票週二開盤報67.75美元。該公司市值為45.7億美元，市盈率為-13.52，貝塔係數為0.46。全球血液治療公司的股價為21.65美元，為52周低點，52周高點為73.02美元。該公司的50日移動均線價格為58.93美元，200日移動均線價格為40.43美元。該公司的流動比率為6.88，速動比率為6.17，債務權益比率為4.92。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
A number of research firms have commented on GBT. Wedbush lowered shares of Global Blood Therapeutics to a "neutral" rating in a research note on Monday, August 15th. JPMorgan Chase & Co. dropped their price target on shares of Global Blood Therapeutics from $39.00 to $36.00 and set a "neutral" rating on the stock in a research note on Tuesday, June 28th. Truist Financial lowered shares of Global Blood Therapeutics to a "hold" rating in a research note on Monday, August 15th. Cantor Fitzgerald reiterated a "neutral" rating on shares of Global Blood Therapeutics in a research note on Wednesday, September 21st. Finally, Canaccord Genuity Group upgraded shares of Global Blood Therapeutics from a "hold" rating to a "buy" rating and boosted their price target for the stock from $40.00 to $72.00 in a research note on Monday, August 8th. Twelve investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $65.50.
許多研究公司都對GBT發表了評論。韋德布什在8月15日星期一的一份研究報告中將全球血液治療公司的股票評級下調至“中性”。摩根大通在6月28日星期二的一份研究報告中將全球血液治療公司的股票目標價從39.00美元下調至36.00美元，並將該股的評級定為“中性”。Truist Financial在8月15日星期一的一份研究報告中將全球血液治療公司的股票評級下調至“持有”。康託·菲茨傑拉德在9月21日星期三的一份研究報告中重申了對全球血液治療公司股票的“中性”評級。最後，Canaccel Genuity Group在8月8日星期一的一份研究報告中將全球血液治療公司的股票評級從“持有”上調至“買入”，並將其股票目標價從40.00美元上調至72.00美元。12名投資分析師對該股的評級為持有，5名分析師對該公司的評級為買入。根據MarketBeat.com的數據，該股目前的平均評級為持有，平均目標價為65.50美元。
Insider Buying and Selling at Global Blood Therapeutics
全球血液治療公司的內幕買賣
In other Global Blood Therapeutics news, insider Nazila Habibizad sold 4,678 shares of the company's stock in a transaction dated Thursday, August 18th. The shares were sold at an average price of $67.19, for a total value of $314,314.82. Following the sale, the insider now owns 8,918 shares of the company's stock, valued at $599,200.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.90% of the company's stock.
在全球血液治療公司的其他消息中，內部人士Nazila Habibizad在一筆日期為8月18日星期四的交易中出售了4678股該公司股票。這些股票的平均價格為67.19美元，總價值為314,314.82美元。出售後，這位內部人士現在擁有8918股該公司股票，價值599,200.42美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可以通過美國證券交易委員會網站。內部人士持有該公司4.90%的股份。
Global Blood Therapeutics Profile
全球血液治療概況
(Get Rating)
(獲取評級)
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
全球血液治療公司是一家生物製藥公司，致力於發現、開發和提供針對服務不足的鐮狀細胞疾病(SCD)患者羣體的治療方法。該公司提供Oxbryta片劑，這是一種治療SCD的口服藥物，每天一次。它還在第二階段對青少年和兒童SCD患者的臨牀試驗中評估了單劑和多劑Oxbryta的安全性和藥代動力學。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
- MO Money: Why Altria Group Stock is Rallying
- Is the Market Overreacting with Shopify Stock?
- Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
- Three Consumer Stocks That Could Outperform In Q4
- 免費獲取StockNews.com關於全球血液治療(GBT)的研究報告
- MarketBeat Podcast，3只股票關注紐蒙特礦業、沃爾瑪、AMC
- Mo Money：奧馳亞集團股價為何上漲
- 市場是否對Shopify Stock反應過度？
- 美聯儲加息：3只股票關注紐蒙特礦業、沃爾瑪、AMC
- 三隻可能在第四季度表現優異的消費類股
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《全球血液治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對全球血液治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。